Answers are grounded in this paper and cite their sources.
Alpha-1 antitrypsin deficiency (AATD) is an inherited, underdiagnosed disorder. This study aimed to estimate the prevalence of AATD-associated genotypes, AATD diagnosis rates, and patient characteristics using data from large epidemiological studies and electronic medical record (EMR)-linked biobanks in the USA. A cross-sectional population of individuals with select AATD genotypes (protease inhibitor [Pi]*MS/MZ/SS/SZ/ZZ) was identified using genetic data from large epidemiological studies and EMR-linked biobanks (All of US [AOU] and BioVU). Genotype prevalence was calculated across all data sources; AATD diagnosis rates and patient characteristics were determined from AOU and BioVU only. The proportion of individuals with ≥ 1 ICD-9/-10-CM diagnosis code for AATD in their EMR was reported overall and by AATD genotype. Across data sources, mean age ranged from 42.6 to 64.2 years, and a numerically higher proportion of participants were female (55.2–63.2% [excluding the WHI cohort where all participants were female]) and White (53.2–92.3%). Pi*ZZ genotype prevalence ranged from 24 to 76 per 100,000 of the population after standardizing prevalence estimates to the US population. AATD diagnosis rates among patients with an AATD genotype were low overall (< 2.0%) but were higher among individuals with a Pi*ZZ genotype (51.5% in AOU; 68.7% in BioVU). Individuals with an AATD diagnosis code had higher rates of liver and lung disease, diabetes, obesity, and thrombocytopenia, and elevated biomarkers of liver disease. This large-scale population-based study demonstrates the low documented AATD diagnosis rates among individuals with AATD-associated genotypes in the USA and underscores the need for improved screening to identify individuals with undiagnosed AATD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: